‘Elrexfio,’ a new bispecific antibody to treat multiple myeloma, is expected to become commercially available soon.

Pfizer Korea has applied for approval of Elrexfio (elranatamab) last year, and it is currently under review by the Ministry of Food and Drug Safety (MFDS), according to industry sources. Elrexfio is expected to be commercially available in the first half of this year.

Last August, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Elrexfio. Elrexfio indication is now approved for patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulato